Hypomania Soon After Shifting From Paroxetine to Agomelatine in a Middle-Aged Woman With Depression

被引：9

作者：

Tu, Kun-Yu

Lin, Pao-Yen

机构：

[1] Kaohsiung Chang Gung Mem Hosp, Dept Psychiat, Kaohsiung, Taiwan

[2] Chang Gung Univ, Coll Med, Kaohsiung 833, Taiwan

来源：

CLINICAL NEUROPHARMACOLOGY | 2014年 / 37卷 / 03期

关键词：

agomelatine; hypomania; paroxetine; ANTIDEPRESSANT; MANIA; DISORDER; SWITCH;

D O I：

10.1097/WNF.0000000000000030

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Hypomania or mania has been reported to be induced by multiple classes of antidepressant agents. Agomelatine is a newly approved drug for treating major depression, and its antidepressant effect works through distinct pharmacodynamic mechanisms from most other commonly used antidepressants. Here, we report a middle-aged female patient who presented hypomanic symptoms shortly after shifting from paroxetine to agomelatine.

引用

收藏

页码：82 / 83

页数：2

相关论文

共 9 条

[1] Switch to mania upon discontinuation of antidepressants in patients with mood disorders: A review of the literature [J].

Ali, S ;

Milev, R .

CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2003, 48 (04) :258-264

[2]

Andrade C, 2004, J CLIN PSYCHIAT, V65, P987

[3] Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder [J].

Berk, M. ;

Dodd, S. ;

Kauer-Sant'Anna, M. ;

Malhi, G. S. ;

Bourin, M. ;

Kapczinski, F. ;

Norman, T. .

ACTA PSYCHIATRICA SCANDINAVICA, 2007, 116 :41-49

[4] Antidepressant-induced mania: an overview of current controversies [J].

Goldberg, JF ;

Truman, CJ .

BIPOLAR DISORDERS, 2003, 5 (06) :407-420

[5] Antidepressant-associated mania: soon after switch from fluoxetine to mirtazapine in an elderly woman with mixed depressive features [J].

Liu, C. C. ;

Liang, K. Y. ;

Liao, S. C. .

JOURNAL OF PSYCHOPHARMACOLOGY, 2009, 23 (02) :220-222

[6] The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways [J].

Millan, MJ ;

Gobert, A ;

Lejeune, F ;

Dekeyne, A ;

Newman-Tancredi, A ;

Pasteau, V ;

Rivet, JM ;

Cussac, D .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 306 (03) :954-964

[7] Synergistic mechanisms involved in the antidepressant effects of agomelatine [J].

Tardito, Daniela ;

Molteni, Raffaella ;

Popoli, Maurizio ;

Racagni, Giorgio .

EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 :S482-S486

[8] Efficacy and Safety of Agomelatine in the Treatment of Major Depressive Disorder A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial [J].

Zajecka, John ;

Schatzberg, Alan ;

Stahl, Stephen ;

Shah, Amy ;

Caputo, Angelika ;

Post, Anke .

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2010, 30 (02) :135-144

[9] Agomelatine - A preliminary review of a new antidepressant [J].

Zupancic, Michael ;

Guilleminault, Christian .

CNS DRUGS, 2006, 20 (12) :981-992